Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
With advances in new cytotoxic drugs and molecular-targeted drugs, the prognosis of patients with metastatic colorectal cancer (mCRC) has improved. However, physicians often hesitate to administer intensive standard regimens to elderly patients with mCRC. Recently, first-line regimens that are effec...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2018-11-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/493849 |
| _version_ | 1811192578173829120 |
|---|---|
| author | Masatsune Shibutani Kiyoshi Maeda Hisashi Nagahara Tatsunari Fukuoka Yasuhito Iseki Shinji Matsutani En Wang Kosei Hirakawa Masaichi Ohira |
| author_facet | Masatsune Shibutani Kiyoshi Maeda Hisashi Nagahara Tatsunari Fukuoka Yasuhito Iseki Shinji Matsutani En Wang Kosei Hirakawa Masaichi Ohira |
| author_sort | Masatsune Shibutani |
| collection | DOAJ |
| description | With advances in new cytotoxic drugs and molecular-targeted drugs, the prognosis of patients with metastatic colorectal cancer (mCRC) has improved. However, physicians often hesitate to administer intensive standard regimens to elderly patients with mCRC. Recently, first-line regimens that are effective in and well-tolerated by patients who are not eligible for intensive chemotherapy have been established. However, the therapeutic strategies to adopt after the failure of first-line treatment for patients who are not eligible for intensive chemotherapy remain unclear. We herein report two cases of long-term control of mCRC via FTD/TPI+bevacizumab (Bmab) as second- or third-line treatment in elderly patients without severe adverse events. In case 1, first-line treatment with Tegafur-Uracil, which is a prodrug of 5-FU, caused disease progression in a short period after the initiation of chemotherapy. In case 2, intensive first-line treatment caused severe adverse events, and treatment was discontinued. However, in both cases, disease control was obtained for a long time without severe adverse events by subsequent treatment with FTD/TPI+Bmab. The success in these present cases indicates that FTD/TPI+Bmab as a second- or third-line treatment is a therapeutic option for elderly patients with mCRC who are not eligible for intensive chemotherapy, even after failure of treatment with 5-FU. |
| first_indexed | 2024-04-11T23:56:04Z |
| format | Article |
| id | doaj.art-2dc076031b684e2697827cd6bdadcf08 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-11T23:56:04Z |
| publishDate | 2018-11-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-2dc076031b684e2697827cd6bdadcf082022-12-22T03:56:22ZengKarger PublishersCase Reports in Oncology1662-65752018-11-0111380080510.1159/000493849493849Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly PatientsMasatsune ShibutaniKiyoshi MaedaHisashi NagaharaTatsunari FukuokaYasuhito IsekiShinji MatsutaniEn WangKosei HirakawaMasaichi OhiraWith advances in new cytotoxic drugs and molecular-targeted drugs, the prognosis of patients with metastatic colorectal cancer (mCRC) has improved. However, physicians often hesitate to administer intensive standard regimens to elderly patients with mCRC. Recently, first-line regimens that are effective in and well-tolerated by patients who are not eligible for intensive chemotherapy have been established. However, the therapeutic strategies to adopt after the failure of first-line treatment for patients who are not eligible for intensive chemotherapy remain unclear. We herein report two cases of long-term control of mCRC via FTD/TPI+bevacizumab (Bmab) as second- or third-line treatment in elderly patients without severe adverse events. In case 1, first-line treatment with Tegafur-Uracil, which is a prodrug of 5-FU, caused disease progression in a short period after the initiation of chemotherapy. In case 2, intensive first-line treatment caused severe adverse events, and treatment was discontinued. However, in both cases, disease control was obtained for a long time without severe adverse events by subsequent treatment with FTD/TPI+Bmab. The success in these present cases indicates that FTD/TPI+Bmab as a second- or third-line treatment is a therapeutic option for elderly patients with mCRC who are not eligible for intensive chemotherapy, even after failure of treatment with 5-FU.https://www.karger.com/Article/FullText/493849Colorectal cancerChemotherapyFTD/TPI + bevacizumabElderly patient |
| spellingShingle | Masatsune Shibutani Kiyoshi Maeda Hisashi Nagahara Tatsunari Fukuoka Yasuhito Iseki Shinji Matsutani En Wang Kosei Hirakawa Masaichi Ohira Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients Case Reports in Oncology Colorectal cancer Chemotherapy FTD/TPI + bevacizumab Elderly patient |
| title | Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients |
| title_full | Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients |
| title_fullStr | Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients |
| title_full_unstemmed | Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients |
| title_short | Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients |
| title_sort | two cases of long term control of metastatic colorectal cancer via ftd tpi plus bevacizumab in elderly patients |
| topic | Colorectal cancer Chemotherapy FTD/TPI + bevacizumab Elderly patient |
| url | https://www.karger.com/Article/FullText/493849 |
| work_keys_str_mv | AT masatsuneshibutani twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT kiyoshimaeda twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT hisashinagahara twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT tatsunarifukuoka twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT yasuhitoiseki twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT shinjimatsutani twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT enwang twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT koseihirakawa twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients AT masaichiohira twocasesoflongtermcontrolofmetastaticcolorectalcancerviaftdtpiplusbevacizumabinelderlypatients |